About Dark Blue Therapeutics
Dark Blue Therapeutics is a Healthcare company based in Oxford (United Kingdom) founded in 2020, and was acquired by Amgen in January 2026. It develops precision medicines for cancer using expert partnerships and drug pipelines. It operates on a B2B model. Dark Blue Therapeutics offers products and services including Precision Oncology Drugs and Drug Pipeline. Its focus areas include Biotechnology, Cancer Research, Therapeutics and Targeted Treatments. Its legal entity is DARK BLUE THERAPEUTICS LTD. Its competitors include Domainex, CatSci and Concept Life Sciences; 2 of its 3 listed competitors have raised funding.
Company details
Dark Blue Therapeutics focuses on reimagining cancer drug discovery by leveraging partnerships with world-leading academic experts. They exploit insights into cancer dependencies and driver mutations to create highly tuned precision medicines for patients with high unmet needs. The company operates from Oxford, United Kingdom, and maintains a pipeline of first-in-class drugs targeting various cancer mechanisms through innovative research and development.
- Headquarters Oxford, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website darkbluetx.com
- Social LinkedIn
- Acquired by Amgen (Jan 2026)
- Legal Name Dark Blue Therapeutics Ltd
- Date of Incorporation 04 Jun, 2020
- Jurisdiction OXFORD, UNITED KINGDOM
Products & Services of Dark Blue Therapeutics
Dark Blue Therapeutics offers a comprehensive portfolio of products and services, including Precision Oncology Drugs and Drug Pipeline.
Targets cancer dependencies for high-need patients through innovative development.
Delivers first-in-class drugs via academic insights and partnerships.
Investors in Dark Blue Therapeutics
Dark Blue Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Amgen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States |
Investor details for Dark Blue Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Dark Blue Therapeutics
2 dated milestones of Dark Blue Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Dark Blue Therapeutics is founded.
- Exit Acquired by Amgen.
Competitors of Dark Blue Therapeutics
Dark Blue Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Domainex, CatSci and Concept Life Sciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| domainex.co.uk | 2001 | Cambridge, United Kingdom | $4.97M | 93 | Drug discovery CRO company for epigenetic research and inflammatory diseases | |
| catsci.com | 2010 | Cardiff, United Kingdom | $5.89M | 63 | Drug discovery services are provided to pharmaceutical clients worldwide. | |
| conceptlifesciences.com | 2014 | Manchester, United Kingdom | International laboratory testing and consultancy in life sciences are offered. |
Detailed competitors of Dark Blue Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Dark Blue Therapeutics
Dark Blue Therapeutics was founded in 2020.
Dark Blue Therapeutics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Dark Blue Therapeutics focuses on reimagining cancer drug discovery by leveraging partnerships with world-leading academic experts. They exploit insights into cancer dependencies and driver mutations to create highly tuned precision medicines for patients with high unmet needs. The company operates from Oxford, United Kingdom, and maintains a pipeline of first-in-class drugs targeting various cancer mechanisms through innovative research and development.
Dark Blue Therapeutics's top competitors include Domainex, Concept Life Sciences and CatSci.
Dark Blue Therapeutics offers Precision Oncology Drugs and Drug Pipeline.
Dark Blue Therapeutics has 1 investor. Key investors include Amgen.
Dark Blue Therapeutics operates through Dark Blue Therapeutics Ltd.
Yes. Dark Blue Therapeutics was acquired by Amgen in January 2026.